In vitro efficacy of sulbactam/durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolates.

ABSTRACT:

Background and objectives

Mycobacterium abscessus has extensive innate and acquired antibiotic resistance resulting in limited antibiotic treatment options and poor clinical outcomes. Currently, the only β-lactam antibiotics with efficacy against M. abscessus are imipenem and cefoxitin. Durlobactam is a β-lactamase inhibitor that may overcome intrinsic resistance mechanisms and enable the use of alternative oral β-lactam antibiotics. The objective of this study was to determine whether sulbactam/durlobactam increases the susceptibility of M. abscessus to alternative β-lactam antibiotics.

Material and methods

Antibiotic susceptibility testing was performed for durlobactam, meropenem, cefuroxime/amoxicillin alone, and sulbactam/durlobactam alone and in combination with meropen

SUBMITTER: Patterson-Fahy K 

PROVIDER: S-EPMC12802925 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature